| SHMT1 knockdown induces apoptosis in lung cancer cells by causing uracil misincorporation A Paone, M Marani, A Fiascarelli, S Rinaldo, G Giardina, R Contestabile, ... Cell death & disease 5 (11), e1525-e1525, 2014 | 119 | 2014 |
| How pyridoxal 5′‐phosphate differentially regulates human cytosolic and mitochondrial serine hydroxymethyltransferase oligomeric state G Giardina, P Brunotti, A Fiascarelli, A Cicalini, MGS Costa, AM Buckle, ... The FEBS journal 282 (7), 1225-1241, 2015 | 92 | 2015 |
| A pyrazolopyran derivative preferentially inhibits the activity of human cytosolic serine hydroxymethyltransferase and induces cell death in lung cancer cells M Marani, A Paone, A Fiascarelli, A Macone, M Gargano, S Rinaldo, ... Oncotarget 7 (4), 4570, 2016 | 58 | 2016 |
| Screening and in vitro testing of antifolate inhibitors of human cytosolic serine hydroxymethyltransferase A Paiardini, A Fiascarelli, S Rinaldo, F Daidone, G Giardina, DR Koes, ... ChemMedChem 10 (3), 490-497, 2015 | 42 | 2015 |
| Differential 3-bromopyruvate inhibition of cytosolic and mitochondrial human serine hydroxymethyltransferase isoforms, key enzymes in cancer metabolic reprogramming A Paiardini, A Tramonti, D Schirch, G Guiducci, ML di Salvo, A Fiascarelli, ... Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics 1864 (11), 1506-1517, 2016 | 40 | 2016 |
| Molecular mechanism of PdxR – a transcriptional activator involved in the regulation of vitamin B6 biosynthesis in the probiotic bacterium Bacillus clausii A Tramonti, A Fiascarelli, T Milano, ML di Salvo, I Nogués, S Pascarella, ... The FEBS journal 282 (15), 2966-2984, 2015 | 37 | 2015 |
| Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models E Gaudio, C Tarantelli, F Spriano, F Guidetti, G Sartori, R Bordone, ... Haematologica 105 (11), 2584, 2020 | 31 | 2020 |
| MEN1309/OBT076, a first-in-class antibody–drug conjugate targeting CD205 in solid tumors G Merlino, A Fiascarelli, M Bigioni, A Bressan, C Carrisi, D Bellarosa, ... Molecular cancer therapeutics 18 (9), 1533-1543, 2019 | 20 | 2019 |
| Characterization of the mechanism of action and efficacy of MEN1611 (PA799), a novel PI3K inhibitor, in breast cancer preclinical models A Fiascarelli, G Merlino, S Capano, A Paoli, A Bressan, M Bigioni, ... Annals of Oncology 30, v781-v782, 2019 | 8 | 2019 |
| Model‐based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2‐positive advanced or metastatic breast cancer patients EM Tosca, E Borella, C Piana, S Bouchene, G Merlino, A Fiascarelli, ... CPT: Pharmacometrics & Systems Pharmacology 12 (11), 1626-1639, 2023 | 7 | 2023 |
| MEN1611, a novel α-selective PI3K inhibitor in solid tumors G Merlino, A Fiascarelli, M Bigioni, A Bressan, C Irrissuto, A Pellacani, ... Cancer Research 78 (13_Supplement), 2160-2160, 2018 | 7 | 2018 |
| Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2+ breast cancer A Fiascarelli, G Merlino, S Capano, S Talucci, D Bisignano, A Bressan, ... Breast Cancer Research and Treatment 199 (1), 13-23, 2023 | 2 | 2023 |
| Combinations containing the anti-CD205 antibody drug conjugate MEN1309/OBT076 show strong pre-clinical activity in diffuse large B cell lymphomas C Tarantelli, E Gaudio, F Spriano, F Guidetti, A Fiascarelli, G Merlino, ... EUROPEAN JOURNAL OF CANCER 103, E65-E66, 2018 | 2 | 2018 |
| Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells TD Dubash, A Bardia, B Chirn, BA Reeves, JA LiCausi, R Burr, BS Wittner, ... Breast Cancer Research and Treatment 201 (1), 43-56, 2023 | 1 | 2023 |
| The novel anti-CD205 antibody drug conjugate (ADC) MEN1309 shows strong antitumoral activity in diffuse large B cell lymphoma (DLBCL) E Gaudio, C Tarantelli, F Guidetti, M Ponzoni, RP Bordone, A Fiascarelli, ... Cancer Research 77 (13_Supplement), 1701-1701, 2017 | 1 | 2017 |
| MEN1703/SEL24 exhibits promising antitumoral activity in preclinical models of myelofibrosis both as single agent and combined with ruxolitinib ML Iannitto, D Bisignano, S Zicari, F Belli, A Fiascarelli, S Talucci, ... Cancer Research 84 (6_Supplement), 665-665, 2024 | | 2024 |
| Tagraxofusp Shows Promising Anti-Tumoral Efficacy in Preclinical in Vitro Models of Myelofibrosis, Both As a Single Agent and in Combination with Janus Kinase Inhibitors ML Iannitto, D Bisignano, A Fiascarelli, S Talucci, S Zicari, F Belli, ... Blood 142, 6329, 2023 | | 2023 |
| The oral SERD Elacestrant in combination with the PI3K inhibitor MEN1611 inhibits tumor growth in ER+/HER2- breast cancer in vitro and in PDX models G Merlino, A Fiascarelli, S Talucci, P Tunici, M Bigioni, A Bressan, ... Cancer Research 83 (7_Supplement), 2849-2849, 2023 | | 2023 |
| PIM Inhibition By SEL24/MEN1703 Combines Synergistically with Gilteritinib in FLT3-ITD Preclinical Models of Acute Myeloid Leukemia D Bellarosa, S Zicari, G Merlino, A Fiascarelli, D Bisignano, F Belli, ... Blood 140 (Supplement 1), 3090-3091, 2022 | | 2022 |
| MEN1112/OBT357, a first-in-class humanized de-fucosylated monoclonal antibody targeting CD157 positive cells in acute myeloid leukemia and myelodysplastic syndrome C Carrisi, D Bellarosa, D Bisignano, A Venditti, F Buccisano, ... Cancer Research 81 (13_Supplement), 1170-1170, 2021 | | 2021 |
